8-Jan-2026 6:00 AM CST - Business Wire Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook #KIT--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced updates on its research and development programs and highlighted upcoming key milestones for 2026. Building on the progress we achieved in our RSV and immunology portfolios this past year, we enter 2026 with strong momentum as we continue to expand our pipeline and deliver
5-Jan-2026 6:00 AM CST - Business Wire Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D., Enantas President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 3:00 p.m. PT in San Francisco, CA. A live webcast of the event will
17-Nov-2025 3:01 PM CST - Business Wire Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal fourth quarter and year-ended September 30, 2025. This past quarter marked a pivotal period for Enanta, with significant progress across our virology and immunology programs, highlighted by positive topline data from the RSVHR study, our Ph
4-Nov-2025 6:00 AM CST - Business Wire Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in the following investor conferences in November and December. Jefferies London Global Healthcare Conference: Fireside Chat on Tuesday, November 18, 2025 at 1:00 p.m. GMT / 8:00 a.m. ET 8th Annual Evercore Healthcare Conf
21-Aug-2025 6:00 AM CST - Business Wire Enanta Pharmaceuticals to Participate in September Investor Conferences Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in three investor conferences in September: Cantor Global Healthcare Conference 2025: Fireside Chat on Wednesday, September 3, 2025 at 8:35 a.m. ET H.C. Wainwright 27th Annual Global Investment Conference: Fireside Chat on Tuesda
11-Aug-2025 3:02 PM CST - Business Wire Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025 #KIT--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal third quarter ended June 30, 2025. This past quarter we continued to make steady progress across our pipeline, marked by the completion of enrollment in the RSVHR trial, a proof-of-concept study of zelicapavir in high-risk adults infected w
5-Aug-2025 6:00 AM CST - Business Wire Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. HCW@Home Series Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in a virtual fireside chat on Tuesday, August 12, 2025 at 1:00 p.m. ET as part of the H.C. Wainwright & Co. HCW@Home series. A live webcast of the event will be accessible by visiting the Events and Presentations section
8-Jan-2026 6:00 AM CST - Business Wire Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook #KIT--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced updates on its research and development programs and highlighted upcoming key milestones for 2026. Building on the progress we achieved in our RSV and immunology portfolios this past year, we enter 2026 with strong momentum as we continue to expand our pipeline and deliver
5-Jan-2026 6:00 AM CST - Business Wire Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D., Enantas President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 3:00 p.m. PT in San Francisco, CA. A live webcast of the event will
17-Nov-2025 3:01 PM CST - Business Wire Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal fourth quarter and year-ended September 30, 2025. This past quarter marked a pivotal period for Enanta, with significant progress across our virology and immunology programs, highlighted by positive topline data from the RSVHR study, our Ph
4-Nov-2025 6:00 AM CST - Business Wire Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in the following investor conferences in November and December. Jefferies London Global Healthcare Conference: Fireside Chat on Tuesday, November 18, 2025 at 1:00 p.m. GMT / 8:00 a.m. ET 8th Annual Evercore Healthcare Conf
21-Aug-2025 6:00 AM CST - Business Wire Enanta Pharmaceuticals to Participate in September Investor Conferences Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in three investor conferences in September: Cantor Global Healthcare Conference 2025: Fireside Chat on Wednesday, September 3, 2025 at 8:35 a.m. ET H.C. Wainwright 27th Annual Global Investment Conference: Fireside Chat on Tuesda
11-Aug-2025 3:02 PM CST - Business Wire Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025 #KIT--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal third quarter ended June 30, 2025. This past quarter we continued to make steady progress across our pipeline, marked by the completion of enrollment in the RSVHR trial, a proof-of-concept study of zelicapavir in high-risk adults infected w
5-Aug-2025 6:00 AM CST - Business Wire Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. HCW@Home Series Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in a virtual fireside chat on Tuesday, August 12, 2025 at 1:00 p.m. ET as part of the H.C. Wainwright & Co. HCW@Home series. A live webcast of the event will be accessible by visiting the Events and Presentations section
